[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
September 18, 2013

A Trial-Based Approach to Statin Guidelines

Author Affiliations
  • 1Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 2Emory Clinical Cardiovascular Research Institute, Atlanta, Georgia
  • 3Atlanta Veterans Administration Medical Center, Atlanta, Georgia
JAMA. 2013;310(11):1123-1124. doi:10.1001/jama.2013.276529

When the last set of US lipid-lowering guidelines was updated in 2004,1 placebo-controlled trials had proven statin therapy to be effective for the secondary prevention of cardiovascular disease. At that time, the ability of these agents to reduce rates of vascular events in primary prevention remained controversial, long-term safety with regard to cancer was unclear, and pharmacologic therapy was relatively expensive.

First Page Preview View Large
First page PDF preview
First page PDF preview
×